Straits Times Index
3,215.35 +41.42 (+1.31%) Nikkei
27,459.77 +514.10 (+1.91%) Hang Seng
19,629.42 +370.66 (+1.92%) FTSE 100
7,536.22 +132.37 (+1.79%) Bitcoin USD
28,268.03 +458.54 (+1.65%) CMC Crypto 200
617.43 +12.38 (+2.05%)
GILD May 2023 80.000 put
| Previous close | 3.6500 |
| Open | 3.3000 |
| Bid | 3.3500 |
| Ask | 3.4500 |
| Strike | 80.00 |
| Expiry date | 2023-05-19 |
| Day's range | 3.3000 - 3.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.16k |
- Zacks
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
- Business Wire
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
SANTA MONICA, Calif., March 21, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-li
- Business Wire
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
FOSTER CITY, Calif. & SAN FRANCISCO, March 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gil
